Corcept Therapeutics マネジメント
マネジメント 基準チェック /34
Corcept Therapeuticsの CEO はJoseph Belanoffで、 Jan1999年に任命され、 の在任期間は 27.58年です。 の年間総報酬は$ 15.30Mで、 7.7%給与と92.3%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の2.65%を直接所有しており、その価値は$ 350.31M 。経営陣と取締役会の平均在任期間はそれぞれ5.8年と24.8年です。
主要情報
Joseph Belanoff
最高経営責任者
US$15.3m
報酬総額
| CEO給与比率 | 7.73% |
| CEO在任期間 | 27.6yrs |
| CEOの所有権 | 2.7% |
| 経営陣の平均在職期間 | 5.8yrs |
| 取締役会の平均在任期間 | 24.8yrs |
経営陣の近況
Recent updates
Seeking Alpha • Aug 21
Like The Knick's, Corcept Rebounded And Is Crushing It
Summary Corcept Therapeutics is rated Strong Buy with $163 one-year and $222 two-year price targets, driven by explosive revenue and margin expansion. Lifyorli’s rapid launch for platinum-resistant ovarian cancer and Korlym’s resilient growth underpin 44%+ revenue growth and 98% gross margins, fueling EPS leverage. Based on my Lifyorli model, Street revenue and EPS estimates could be significantly low. Upcoming catalysts include an FDA decision on Relacorilant for Cushing syndrome, European approvals, and key trial results, with significant upside if milestones are met. CORT’s broad pipeline, cash-rich balance sheet, and aggressive salesforce expansion position it as a platform company addressing major disease categories. Read the full article on Seeking Alpha
ナラティブ更新 • Aug 20
CORT: Ovarian Cancer Launch Will Shape Future Upside Outlook
Corcept Therapeutics' updated analyst price target has shifted from $88 to $141, reflecting analysts' focus on higher projected revenue growth, a revised future P/E near 21, and the potential impact of products like relacorilant and Lifyorli highlighted in recent research. Analyst Commentary Recent research on Corcept Therapeutics gives you a mix of strong optimism and pointed caution.
ナラティブ更新 • Aug 06
CORT: Elevated Expectations Around Cushing’s Decision Will Shape Bearish Risk Outlook
Corcept Therapeutics' updated fair value estimate has moved from $88 to $50. This reflects analysts' wider range of views after several firms sharply raised their price targets into the $95 to $165 band, based on stronger recent results, expanded 2026 revenue guidance, and growing confidence in Lifyorli, Korlym, and the broader pipeline.分析記事 • Aug 05
We Think That There Are More Issues For Corcept Therapeutics (NASDAQ:CORT) Than Just Sluggish Earnings
Following the release of a lackluster earnings report from Corcept Therapeutics Incorporated ( NASDAQ:CORT ) the stock...ナラティブ更新 • Jul 23
CORT: Regulatory Reset And New Indications Will Shape Balanced Risk Reward Outlook
For Corcept Therapeutics, the analyst-derived fair value estimate has been revised from $50 to $88, with analysts linking the higher target and increased assumed revenue growth to recent positive relacorilant regulatory updates and the potential for an additional indication. Analyst Commentary Recent research around Corcept Therapeutics highlights a mix of optimism around relacorilant and Lifyorli alongside pockets of caution, which matters if you are weighing how much execution or regulatory risk to price into the stock.ナラティブ更新 • Jul 09
CORT: Regulatory Uncertainty Around Key NDA Resubmission Will Drive Future Downside Risk
Corcept Therapeutics' updated analyst price target of $50, down from $95, reflects analysts incorporating lower projected revenue growth, a slightly higher discount rate, and a more conservative future P/E multiple, even as they factor in improved profit margin assumptions and recent positive relacorilant and Lifyorli milestones. Analyst Commentary Recent Street research on Corcept Therapeutics has centered on the regulatory path for relacorilant, the commercial outlook for Lifyorli in ovarian cancer, and how these factors feed into valuation assumptions.ナラティブ更新 • Jun 25
CORT: Ovarian Cancer Launch And Cushing’s Review Will Shape Balanced Outlook
Analysts have lifted their price targets on Corcept Therapeutics to a range of $72 to $135, citing the positive relacorilant NDA resubmission, the recent Lifyorli approval, and greater clarity on the regulatory path as key reasons for the higher valuation views. Analyst Commentary Recent research on Corcept Therapeutics points to a more constructive view on the stock, with several firms lifting price targets after the relacorilant NDA resubmission and the approval of Lifyorli.ナラティブ更新 • Jun 06
CORT: Ovarian Cancer Data And Cushing’s Resubmission Will Drive Future Upside
Corcept Therapeutics' updated analyst price target has increased to $88.00 from $73.40, reflecting analysts' focus on recent price target revisions associated with the relacorilant NDA resubmission and the launch of Lifyorli in ovarian cancer. Analyst Commentary Recent Street research around Corcept Therapeutics centers on two main themes, the relacorilant regulatory path and the commercial opportunity for Lifyorli in ovarian cancer, with both feeding directly into updated valuation work.ナラティブ更新 • May 11
CORT: New Ovarian Cancer Therapy Approval Will Support Future Upside
Analysts have raised Corcept Therapeutics' implied fair value target to $73.40 from $67.40. This reflects updated assumptions that indicate higher revenue growth and profit margins, slightly offset by a higher discount rate and a lower future P/E multiple following recent mixed price target revisions and a rating upgrade on the stock.ナラティブ更新 • Apr 25
CORT: Ovarian Cancer Approval Will Support Future Upside Despite Patent Setback
Analysts have adjusted their price targets on Corcept Therapeutics, with changes such as H.C. Wainwright moving its target to $67, alongside offsetting increases from firms like Canaccord. These moves reflect updated views on patent risk, generic competition and the long term earnings profile implied by largely unchanged fair value, revenue growth, profit margin and future P/E assumptions.ナラティブ更新 • Apr 11
CORT: Ovarian Cancer Approval Will Support Future Upside Despite Generic Headwinds
Corcept Therapeutics' updated analyst price target has been reset to $67, with analysts citing a tempered revenue growth outlook, slightly stronger expected profit margins, and an unchanged fair value and future P/E assumption. Analyst Commentary Recent Street research on Corcept Therapeutics reflects a mixed but engaged view, with several firms recalibrating price targets and ratings after legal and regulatory updates.ナラティブ更新 • Mar 27
CORT: Ovarian Cancer Approval Will Drive Future Upside Despite Generic Risk
Corcept Therapeutics' updated analyst price target has moved to $67.40 from $65.40. Analysts cite refined fair value assumptions and a slightly higher future P/E multiple as they reassess the stock following mixed target changes across recent research coverage.ナラティブ更新 • Mar 10
CORT: Future Generic Ruling And Oncology Data Will Drive Upside
Analysts have reduced their price target on Corcept Therapeutics to $67 from $105, reflecting lower fair value assumptions and revised expectations for revenue growth and profit margins after the court ruling that allows Teva's generic Korlym to participate in the Cushing's syndrome market. Analyst Commentary Recent research on Corcept Therapeutics clusters around the patent ruling on Teva's generic Korlym and its implications for the Cushing's syndrome market.ナラティブ更新 • Feb 24
CORT: Future Court Ruling And Oncology Data Will Drive Long Term Upside
Analysts have reduced their fair value estimate for Corcept Therapeutics from $94.20 to $76.40 and the implied future P/E from 18.66x to 16.90x, reflecting a lower price target from $105 to $67 following the court decision allowing Teva's generic Korlym to compete, along with a more cautious view on revenue growth and profit margins. Analyst Commentary Recent research updates on Corcept Therapeutics focus heavily on the legal outcome around Teva's generic Korlym and what that could mean for valuation, growth expectations, and execution risk.ナラティブ更新 • Feb 09
CORT: Future Regulatory And Oncology Outcomes Will Drive Long Term Upside
Analysts have raised their price target on Corcept Therapeutics by about $1, citing updated models that reflect steady assumptions for fair value, revenue growth, profit margins and future P/E. Recent research maintains the overall investment thesis despite regulatory developments.ナラティブ更新 • Jan 26
CORT: Future Endocrine And Oncology Decisions Will Drive Long Term Upside
Narrative Update: Corcept Therapeutics Analysts have lifted their fair value estimate for Corcept Therapeutics to $94.20 from $91.00, citing updated assumptions around higher revenue growth, stronger profit margins, and a slightly lower future P/E multiple in their latest models. Analyst Commentary Recent research on Corcept Therapeutics has focused on how its Cushing's syndrome franchise could support long term growth, while also highlighting uncertainties around future positioning and execution.ナラティブ更新 • Jan 10
CORT: Upcoming Endocrine And Oncology Decisions Will Shape Long Term Upside
Analysts have reset their price target framework for Corcept Therapeutics from about $127 to roughly $91, reflecting updated assumptions around revenue growth, profit margins, and a higher future P/E multiple, informed in part by recent coverage that compares relacorilant and Korlym with existing Cushing's syndrome treatments. Analyst Commentary Street research around Corcept Therapeutics is limited in the recent set of notes, but one new initiation helps frame how some investors might think about both the clinical and valuation setup for the stock.分析記事 • Jan 01
The Price Is Right For Corcept Therapeutics Incorporated (NASDAQ:CORT) Even After Diving 56%
Corcept Therapeutics Incorporated ( NASDAQ:CORT ) shareholders that were waiting for something to happen have been...ナラティブ更新 • Dec 17
CORT: Upcoming Ovarian Cancer Decisions May Drive Upside Despite Pharmacy Transition Risks
Analysts have modestly trimmed their price target on Corcept Therapeutics to $127.20 from $134.50, reflecting a slightly higher discount rate. They also point to stronger long term revenue growth, expanding profit margins and a lower future P E multiple supported by continued confidence in the commercial potential of Korlym and relacorilant.分析記事 • Oct 07
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 30% But Its P/E Still Looks Reasonable
The Corcept Therapeutics Incorporated ( NASDAQ:CORT ) share price has done very well over the last month, posting an...CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$54m |
| Mar 31 2026 | n/a | n/a | US$47m |
| Dec 31 2025 | US$15m | US$1m | US$98m |
| Sep 30 2025 | n/a | n/a | US$105m |
| Jun 30 2025 | n/a | n/a | US$132m |
| Mar 31 2025 | n/a | n/a | US$133m |
| Dec 31 2024 | US$10m | US$1m | US$140m |
| Sep 30 2024 | n/a | n/a | US$140m |
| Jun 30 2024 | n/a | n/a | US$125m |
| Mar 31 2024 | n/a | n/a | US$117m |
| Dec 31 2023 | US$9m | US$1m | US$105m |
| Sep 30 2023 | n/a | n/a | US$91m |
| Jun 30 2023 | n/a | n/a | US$94m |
| Mar 31 2023 | n/a | n/a | US$94m |
| Dec 31 2022 | US$7m | US$896k | US$101m |
| Sep 30 2022 | n/a | n/a | US$117m |
| Jun 30 2022 | n/a | n/a | US$113m |
| Mar 31 2022 | n/a | n/a | US$112m |
| Dec 31 2021 | US$11m | US$844k | US$113m |
| Sep 30 2021 | n/a | n/a | US$106m |
| Jun 30 2021 | n/a | n/a | US$98m |
| Mar 31 2021 | n/a | n/a | US$99m |
| Dec 31 2020 | US$6m | US$770k | US$106m |
| Sep 30 2020 | n/a | n/a | US$109m |
| Jun 30 2020 | n/a | n/a | US$114m |
| Mar 31 2020 | n/a | n/a | US$106m |
| Dec 31 2019 | US$5m | US$708k | US$94m |
報酬と市場: Josephの 総報酬 ($USD 15.30M ) は、 US市場 ($USD 14.46M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Josephの報酬は 20% 以上増加しましたが、会社の収益は過去 1 年間で 20% 以上減少しました。
CEO
Joseph Belanoff (69 yo)
27.6yrs
在職期間
US$15,303,551
報酬
Dr. Joseph K. Belanoff, M.D., is a Co-Founder of Corcept Therapeutics Incorporated and has been its Chief Executive Officer since 1999 and President since 2014. Dr. Belanoff has been a Faculty Member and h...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | 27.6yrs | US$15.30m | 2.65% $ 350.3m | |
| CFO & Treasurer | 5.4yrs | US$6.14m | 0.015% $ 2.0m | |
| President of Endocrinology | 10.3yrs | US$6.21m | 0.11% $ 14.6m | |
| Chief Development Officer | 5yrs | US$6.34m | 0.0037% $ 487.6k | |
| Chief Business Officer & Secretary | 12.6yrs | US$6.38m | 0.078% $ 10.3m | |
| Chief Technology & Accounting Officer | 6.1yrs | データなし | 0.0051% $ 671.3k | |
| Chief Scientific Officer | 6.1yrs | US$3.11m | 0.24% $ 31.2m | |
| Chief Human Resources & Communications Officer | 5.1yrs | データなし | データなし | |
| President of Emerging Markets | 2.8yrs | データなし | データなし | |
| President of Oncology | 2.6yrs | データなし | データなし |
5.8yrs
平均在職期間
55.5yo
平均年齢
経験豊富な経営陣: CORTの経営陣は経験豊富で経験豊富です（平均在職期間は5.8年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | 27.6yrs | US$15.30m | 2.65% $ 350.3m | |
| Independent Director | 27.6yrs | US$768.00k | 5.13% $ 678.5m | |
| Independent Director | 22.1yrs | US$784.50k | 1.07% $ 141.8m | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Chairman | 27.6yrs | US$1.29m | 1.36% $ 180.3m | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 6.4yrs | US$787.00k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 6.9yrs | US$764.99k | 0% $ 0 |
24.8yrs
平均在職期間
70.5yo
平均年齢
経験豊富なボード: CORTの 取締役会 は経験豊富で 経験豊富 です ( 24.8年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/24 19:08 |
| 終値 | 2026/08/21 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Corcept Therapeutics Incorporated 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。19
| アナリスト | 機関 |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Debjit Chattopadhyay | Brean Capital Historical (Janney Montgomery) |
| David Buck | B. Riley Securities, Inc. |